User profiles for J. Castelli

Joel Castelli

Centre Eugene Marquis
Verified email at rennes.unicancer.fr
Cited by 2823

Adaptive radiotherapy for head and neck cancer

J Castelli, A Simon, C Lafond, N Perichon… - Acta …, 2018 - Taylor & Francis
Introduction: Large anatomical variations can be observed during the treatment course
intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC), leading to potential …

The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership

E Chajon, J Castelli, H Marsiglia… - Critical reviews in …, 2017 - Elsevier
Radiotherapy (RT) is one of the main components in the treatment of cancer. The better
understanding of the immune mechanisms associated with tumor establishment and how RT …

Deformable image registration for radiation therapy: principle, methods, applications and evaluation

B Rigaud, A Simon, J Castelli, C Lafond, O Acosta… - Acta …, 2019 - Taylor & Francis
Background: Deformable image registration (DIR) is increasingly used in the field of radiation
therapy (RT) to account for anatomical deformations. The aims of this paper are to describe …

[HTML][HTML] Treatment of Fabry's disease with the pharmacologic chaperone migalastat

…, N Skuban, J Castelli, J Barth… - New england journal …, 2016 - Mass Medical Soc
Background Fabry’s disease, an X-linked disorder of lysosomal α-galactosidase deficiency,
leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic …

[HTML][HTML] Head and neck tumor segmentation in PET/CT: the HECKTOR challenge

…, H Elhalawani, J Castelli, M Vallières, S Zhu, J Xie… - Medical image …, 2022 - Elsevier
This paper relates the post-analysis of the first edition of the HEad and neCK TumOR (HECKTOR)
challenge. This challenge was held as a satellite event of the 23rd International …

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT …

…, C Barlow, N Skuban, JP Castelli, J Barth… - Journal of medical …, 2017 - jmg.bmj.com
Background Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations,
resulting in α-galactosidase (α-Gal) deficiency and accumulation of lysosomal substrates…

[HTML][HTML] The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

…, J Barth, C Barlow, KJ Valenzano, J Castelli… - Genetics in …, 2017 - nature.com
Purpose: Fabry disease is an X-linked lysosomal storage disorder caused by mutations in
the α-galactosidase A gene. Migalastat, a pharmacological chaperone, binds to specific …

A study of the interferon antiviral mechanism: apoptosis activation by the 2–5A system

JAC Castelli, BA Hassel, KA Wood, XL Li… - The Journal of …, 1997 - rupress.org
The 2–5A system contributes to the antiviral effect of interferons through the synthesis of 2–5A
and its activation of the ribonuclease, RNase L. RNase L degrades viral and cellular RNA …

[HTML][HTML] Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies

…, C Rousseau, A Mervoyer, C Reinhold, J Castelli… - Scientific reports, 2020 - nature.com
Multicenter studies are needed to demonstrate the clinical potential value of radiomics as a
prognostic tool. However, variability in scanner models, acquisition protocols and …

Evaluating plant–soil feedback together with competition in a serpentine grassland

BB Casper, JP Castelli - Ecology letters, 2007 - Wiley Online Library
Plants can alter biotic and abiotic soil characteristics in ways that feedback to change the
performance of that same plant species relative to co‐occurring plants. Most evidence for this …